N-benzyl-2-phenoxybenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-2-phenoxybenzamide
• 化学式: C₂₀H₁₇NO₂
• mdl: MFCD02625465
• 分子量: 303.4
• InChiKey: HHDNKOZHUOHVTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS
  申请人：MEDIBIOFARMA, S.L.

  公开号：EP3693359A1

  公开（公告）日：2020-08-12

  The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I) as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.

  本发明涉及一种新型、可选择取代的N-苄基-2-苯氧基苯甲酰衍生物，其化学式为(I)，作为前列腺素E2（PGE2）的EP4和/或EP2受体调节剂，以及其制备方法、包含所述化合物的药物组合物和用于治疗可以通过调节前列腺素E2（PGE2）的EP4和/或EP2受体而改善的病理状况、紊乱或疾病的化合物，如癌症、疼痛、炎症、神经退行性疾病和肾脏疾病。
• [EN] NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS<br/>[FR] NOUVEAUX DÉRIVÉS DE N-BENZYL-2-PHÉNOXYBENZAMIDE UTILISÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DE LA PROSTAGLANDINE E2 (PGE2)
  申请人：MEDIBIOFARMA SL

  公开号：WO2020161275A1

  公开（公告）日：2020-08-13

  The present invention relates to novel, optionally substituted, N-benzyl-2- phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.